Ekaterina Nailyevna Dudinskaya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ekaterina Nailyevna Dudinskaya has a total of 493 co-authors. Here are the top co-authors by number of shared publications:
- Olga Nikolaevna Tkacheva
Russian Gerontology Clinical Research Center of Pirogov Russian National Research Medical University
58 shared publications - Yu. V. Kotovskaya
Russian Clinical and Research Center of Gerontology, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
23 shared publications O. N. Tkacheva
Department of Aging Diseases, Faculty of Additional Professional Education, Pirogov Russian National Research Medical University, Moscow, Russia
18 shared publications- Lubov V. Matchekhina
Russian Gerontology Research and Clinical Centre, Pirogov National Research Medical University, Moscow 129226, Russia
17 shared publications - Sergey Anatolyevich Boytsov
E.I. Chazov National Medical Research Center of Cardiology of the Ministry of Health of the Russia
15 shared publications D. U. Akasheva
14 shared publications
Latest Publications
- Open Access
- 19 October 2026
- Published by Sechenov University in National Health Care (Russia)
- Vol. 7 (2) , 27-38
Sarcopenia in older patients with type 2 diabetes mellitus: detection and care pathways in Russian clinical practice
Sarcopenia is a significant clinical and socio-medical problem in patients with type 2 diabetes mellitus (T2DM), particularly in older age groups. This review summarizes current evidence on the prevalence and clinical consequences of sarcopenia in T2DM and discusses screening and diagnostic methods and their applicability in Russian clinical practice. The potential of anthropometry, handgrip dynamometry, physical performance tests, the SARC-F and SARC-CalF questionnaires, the Ishii score, and instrumental assessment of muscle mass is described. Particular attention is paid to the limitations of diagnostic methods in patients with obesity, chronic kidney disease, peripheral edema, diabetic polyneuropathy, and other complications of T2DM. The provisions of the 2026 Russian clinical guidelines are analyzed, and an approach to incorporating sarcopenia screening into the existing follow-up system for patients with T2DM is proposed. Resource, workforce, and information requirements for implementation, potential performance indicators, and directions for future research are discussed. The need to validate diagnostic tools, evaluate clinical effectiveness, and conduct costeffectiveness studies in the Russian T2DM population is emphasized.
- 19 October 2026
- Published by Sechenov University in National Health Care (Russia)
- Vol. 7 (2) , 27-38
Open AccessSarcopenia in older patients with type 2 diabetes mellitus: detection and care pathways in Russian clinical practice
Sarcopenia is a significant clinical and socio-medical problem in patients with type 2 diabetes mellitus (T2DM), particularly in older age groups. This review summarizes current evidence on the prevalence and clinical consequences of sarcopenia in T2DM and discusses screening and diagnostic methods and their applicability in Russian clinical practice. The potential of anthropometry, handgrip dynamometry, physical performance tests, the SARC-F and SARC-CalF questionnaires, the Ishii score, and instrumental assessment of muscle mass is described. Particular attention is paid to the limitations of diagnostic methods in patients with obesity, chronic kidney disease, peripheral edema, diabetic polyneuropathy, and other complications of T2DM. The provisions of the 2026 Russian clinical guidelines are analyzed, and an approach to incorporating sarcopenia screening into the existing follow-up system for patients with T2DM is proposed. Resource, workforce, and information requirements for implementation, potential performance indicators, and directions for future research are discussed. The need to validate diagnostic tools, evaluate clinical effectiveness, and conduct costeffectiveness studies in the Russian T2DM population is emphasized.
- Open Access
- 24 September 2026
- Published by Sechenov University in Sechenov Medical Journal
- Vol. 17 (2) , 4-16
Contemporary sarcopenia diagnosis: evolving definitions, screening, and instrumental assessment – a narrative review
Sarcopenia currently affects 10–27% of people worldwide and 30–37% in the Russian Federation. Its social burden is considerable: the condition is associated with fractures, disability, and increased mortality. Sarcopenia nonetheless remains underdiagnosed. Diagnosis is hindered by the absence of universal criteria, standardized cutoff values, and widely available screening tools, while applying non-adapted foreign reference values to the Russian population may cause both under- and overdiagnosis. Aim. To analyze the evolution of international and Russian approaches to sarcopenia diagnosis, assess the diagnostic value and limitations of available screening and instrumental methods, and formulate proposals for optimizing diagnostic strategies in clinical practice in the Russian Federation. Materials and methods. A literature review on sarcopenia diagnosis was conducted using PubMed/MEDLINE, Scopus, Google Scholar, and eLibrary.ru for 2006–2026. Systematic reviews, meta-analyses, randomized controlled trials and cohort studies, consensus documents, and clinical guidelines were included. Results. A shift was observed from the isolated assessment of muscle mass toward diagnostic models in which muscle strength serves as the primary criterion and physical performance as an indicator of disease severity. Handgrip dynamometry cutoff values varied across populations. In particular, muscle strength in Russians older than 65 years was at the lower limit of European reference values. No screening instrument demonstrated both high sensitivity and high specificity. The most balanced instrument, SARC-CalF, has not been validated in the Russian population. Instrumental methods are highly accurate; however, their use is limited by high cost, limited availability, dependence on hydration status, and the lack of standardized protocols. Conclusion. To improve the effectiveness of sarcopenia diagnosis in Russia, national reference values should be developed, diagnostic protocols standardized, and screening instruments validated.
- 24 September 2026
- Published by Sechenov University in Sechenov Medical Journal
- Vol. 17 (2) , 4-16
Open AccessContemporary sarcopenia diagnosis: evolving definitions, screening, and instrumental assessment – a narrative review
Sarcopenia currently affects 10–27% of people worldwide and 30–37% in the Russian Federation. Its social burden is considerable: the condition is associated with fractures, disability, and increased mortality. Sarcopenia nonetheless remains underdiagnosed. Diagnosis is hindered by the absence of universal criteria, standardized cutoff values, and widely available screening tools, while applying non-adapted foreign reference values to the Russian population may cause both under- and overdiagnosis. Aim. To analyze the evolution of international and Russian approaches to sarcopenia diagnosis, assess the diagnostic value and limitations of available screening and instrumental methods, and formulate proposals for optimizing diagnostic strategies in clinical practice in the Russian Federation. Materials and methods. A literature review on sarcopenia diagnosis was conducted using PubMed/MEDLINE, Scopus, Google Scholar, and eLibrary.ru for 2006–2026. Systematic reviews, meta-analyses, randomized controlled trials and cohort studies, consensus documents, and clinical guidelines were included. Results. A shift was observed from the isolated assessment of muscle mass toward diagnostic models in which muscle strength serves as the primary criterion and physical performance as an indicator of disease severity. Handgrip dynamometry cutoff values varied across populations. In particular, muscle strength in Russians older than 65 years was at the lower limit of European reference values. No screening instrument demonstrated both high sensitivity and high specificity. The most balanced instrument, SARC-CalF, has not been validated in the Russian population. Instrumental methods are highly accurate; however, their use is limited by high cost, limited availability, dependence on hydration status, and the lack of standardized protocols. Conclusion. To improve the effectiveness of sarcopenia diagnosis in Russia, national reference values should be developed, diagnostic protocols standardized, and screening instruments validated.
- Open Access
- 9 September 2026
- Published by Consilium Medicum in Consilium Medicum
- Vol. 28 (8) , 577-588
Anti-resorptive therapy with denosumab in elderly and senile patients with osteoporosis: a narrative review and clinical recommendations
Senile osteoporosis represents one of the most pressing challenges in modern geriatric medicine, characterized by high prevalence, delayed diagnosis, and severe complications such as low-energy fractures, which are associated with disability, loss of independence, and significantly increased mortality. The pathogenetic mechanisms underlying fracture development in the elderly are multifactorial, encompassing not only bone loss but also sarcopenia, increased fall risk, and comorbid conditions, necessitating a comprehensive therapeutic approach. Denosumab, a fully human monoclonal antibody against RANKL, occupies a pivotal position in the management of senile osteoporosis due to its potent anti-resorptive activity, convenient subcutaneous administration once every 6 months, and favourable safety profile, as confirmed in 10-year clinical trials. This narrative review presents current evidence on the epidemiology of senile osteoporosis, the pathogenesis of its complications, and the place of denosumab in treatment algorithms according to current clinical guidelines. Particular emphasis is placed on practical aspects of denosumab use in geriatric patients: preparation with calcium and vitamin D supplementation, management of patients with chronic kidney disease, post-fracture treatment strategy, utilization in long-term care facilities, as well as potential pleiotropic effects, including impact on fall risk, type 2 diabetes mellitus, osteoarthritis, cardiovascular system, and muscle mass. The review is based on data derived from randomized controlled trials, meta-analyses, retrospective cohort studies, and real-world clinical practice. Evidence indicates that, while demonstrating comparable efficacy to bisphosphonates, denosumab exhibits a more favourable safety profile, which is of particular importance in frail elderly patients. Special consideration is given to the recent introduction of the denosumab biosimilar – Forsedeno® – onto the Russian pharmaceutical market, which substantially enhances the accessibility of long-term anti-resorptive therapy. The feasibility of prolonged, including lifelong, denosumab therapy in older patients is substantiated, taking into account the persistently elevated risk of recurrent fractures and the favourable long-term safety profile of the drug.
- 9 September 2026
- Published by Consilium Medicum in Consilium Medicum
- Vol. 28 (8) , 577-588
Open AccessAnti-resorptive therapy with denosumab in elderly and senile patients with osteoporosis: a narrative review and clinical recommendations
Senile osteoporosis represents one of the most pressing challenges in modern geriatric medicine, characterized by high prevalence, delayed diagnosis, and severe complications such as low-energy fractures, which are associated with disability, loss of independence, and significantly increased mortality. The pathogenetic mechanisms underlying fracture development in the elderly are multifactorial, encompassing not only bone loss but also sarcopenia, increased fall risk, and comorbid conditions, necessitating a comprehensive therapeutic approach. Denosumab, a fully human monoclonal antibody against RANKL, occupies a pivotal position in the management of senile osteoporosis due to its potent anti-resorptive activity, convenient subcutaneous administration once every 6 months, and favourable safety profile, as confirmed in 10-year clinical trials. This narrative review presents current evidence on the epidemiology of senile osteoporosis, the pathogenesis of its complications, and the place of denosumab in treatment algorithms according to current clinical guidelines. Particular emphasis is placed on practical aspects of denosumab use in geriatric patients: preparation with calcium and vitamin D supplementation, management of patients with chronic kidney disease, post-fracture treatment strategy, utilization in long-term care facilities, as well as potential pleiotropic effects, including impact on fall risk, type 2 diabetes mellitus, osteoarthritis, cardiovascular system, and muscle mass. The review is based on data derived from randomized controlled trials, meta-analyses, retrospective cohort studies, and real-world clinical practice. Evidence indicates that, while demonstrating comparable efficacy to bisphosphonates, denosumab exhibits a more favourable safety profile, which is of particular importance in frail elderly patients. Special consideration is given to the recent introduction of the denosumab biosimilar – Forsedeno® – onto the Russian pharmaceutical market, which substantially enhances the accessibility of long-term anti-resorptive therapy. The feasibility of prolonged, including lifelong, denosumab therapy in older patients is substantiated, taking into account the persistently elevated risk of recurrent fractures and the favourable long-term safety profile of the drug.
- Open Access
- 9 September 2026
- Published by Consilium Medicum in Consilium Medicum
- Vol. 28 (8) , 571-576
Nutritional rehabilitation of elderly and senile patients with non-dialysis chronic kidney disease. Case report
A low-protein diet has traditionally been used to mitigate the progression of uremic symptoms and to decrease the production of nitrogen-catabolism products in patients with chronic kidney disease (CKD). CKD is prevalent among individuals over 65, and its progression leads to a decline in nutritional status, particularly in protein-energy deficiency, muscle weakness, and functional limitations. These issues are further exacerbated by aging. Malnutrition is regarded as a significant factor in the multifactorial causes of sarcopenia and senile asthenia. Eating disorders in elderly and senile patients are associated with an increased incidence of infections, prolonged and more frequent hospitalizations, extended recovery times, elevated fracture risks, dependency on external assistance, a decline in quality of life, and a higher mortality rate. This situation necessitates the implementation of appropriate medical rehabilitation strategies that consider the complexities of comorbidity and nutritional disorders in these patients. The mechanisms that drive the development of CKD and various geriatric syndromes, such as malnutrition, sarcopenia, and falls, are intricate. They include metabolic acidosis, oxidative stress, overproduction of pro-inflammatory cytokines, secondary hyperparathyroidism, decreased vitamin D levels, and chronic anemia, all of which contribute to reduced physical activity and diminished food intake. Given such complex mechanisms, nutritional support and non-nutritional therapeutic interventions in CKD patients should encompass a range of strategies, including dietary restrictions and dietary supplements. When managing older adults with CKD, physicians face a challenging decision in dietary planning: recommendations to maintain protein intake at 1.2–1.5 g/kg/day to avert malnutrition and sarcopenia must be carefully weighed against nephrologists' advice to limit protein intake to slow CKD progression. This article outlines recommendations for nutritional support in elderly patients with renal impairment and includes a clinical case demonstrating nutritional rehabilitation within a geriatric department.
- 9 September 2026
- Published by Consilium Medicum in Consilium Medicum
- Vol. 28 (8) , 571-576
Open AccessNutritional rehabilitation of elderly and senile patients with non-dialysis chronic kidney disease. Case report
A low-protein diet has traditionally been used to mitigate the progression of uremic symptoms and to decrease the production of nitrogen-catabolism products in patients with chronic kidney disease (CKD). CKD is prevalent among individuals over 65, and its progression leads to a decline in nutritional status, particularly in protein-energy deficiency, muscle weakness, and functional limitations. These issues are further exacerbated by aging. Malnutrition is regarded as a significant factor in the multifactorial causes of sarcopenia and senile asthenia. Eating disorders in elderly and senile patients are associated with an increased incidence of infections, prolonged and more frequent hospitalizations, extended recovery times, elevated fracture risks, dependency on external assistance, a decline in quality of life, and a higher mortality rate. This situation necessitates the implementation of appropriate medical rehabilitation strategies that consider the complexities of comorbidity and nutritional disorders in these patients. The mechanisms that drive the development of CKD and various geriatric syndromes, such as malnutrition, sarcopenia, and falls, are intricate. They include metabolic acidosis, oxidative stress, overproduction of pro-inflammatory cytokines, secondary hyperparathyroidism, decreased vitamin D levels, and chronic anemia, all of which contribute to reduced physical activity and diminished food intake. Given such complex mechanisms, nutritional support and non-nutritional therapeutic interventions in CKD patients should encompass a range of strategies, including dietary restrictions and dietary supplements. When managing older adults with CKD, physicians face a challenging decision in dietary planning: recommendations to maintain protein intake at 1.2–1.5 g/kg/day to avert malnutrition and sarcopenia must be carefully weighed against nephrologists' advice to limit protein intake to slow CKD progression. This article outlines recommendations for nutritional support in elderly patients with renal impairment and includes a clinical case demonstrating nutritional rehabilitation within a geriatric department.
- Open Access
- 6 September 2026
- Published by Autonomous non-profit organization-Society of Specialists in the Field Innovative Medical Technology in Russian Journal of Geriatric Medicine
- No. 3,p. 260-269
Assessment of Nutritional Status in Older Adults Using the Mini Nutritional Assessment: Patterns of Impairments and Targets for Dietary Rehabilitation. Analysis of the Multicenter Prospective Study «POSTSCRIPTUM»
BACKGROUND . Frailty and related nutritional disorders are highly prevalent among older adults, especially in inpatient settings [1, 2]. The Mini Nutritional Assessment (MNA) is a validated tool that enables not only screening of nutritional status but also a more detailed evaluation of risk factors for developing malnutrition [3]. OBJECTIVE — to conduct a comprehensive evaluation of nutritional parameters in patients aged 60 years and older residing in care homes and geriatric centers in Moscow, to detail responses across MNA domains, to identify correlations with functional, psychoemotional and clinical parameters, and to propose targets for dietary interventions. MATERIALS AND METHODS. A multicenter prospective study (within the first phase of the «POSTSCRIPTUM» clinical trial) included 792 patients aged 60 years and older (mean age 76.8 ± 8.2 years, 68% women) with indications for geriatric rehabilitation. Nutritional assessment was performed using the full version of the MNA [3]. Based on the total score, patients were divided into two groups: «normal» (MNA ≥24, n = 636) and «at risk of malnutrition» (MNA < 24, n = 156). A comparative analysis of responses to each of the 18 MNA items was carried out, along with correlation analysis between the MNA score and age, body mass index (BMI), functional independence (Barthel Index, Lawton Index), physical performance (Short Physical Performance Battery, SPPB), muscle strength (handgrip dynamometry), cognitive status (Montreal Cognitive Assessment (MoCA), depression (15-item Geriatric Depression Scale, GDS-15), pain (Visual Analogue Scale, VAS score), insomnia (Insomnia Severity Index, ISI), polypharmacy, and frailty screening (score on the «Age Is Not a Hindrance» scale). RESULTS . The proportion of patients at risk of malnutrition was 19.7%. Statistically significant differences between groups were found across most MNA domains (p < 0.001). The following factors were significantly more frequent in the malnutrition-risk group: appetite decline (46.8% moderate and 1.3% severe), weight loss over the preceding 3 months (43.6%), mobility limitations (5.8%), acute stress/disease (69.2%), neuropsychological problems (overt dementia or depression —15.4%), polypharmacy (80.8%), pressure ulcers (2.6%), inadequate meal frequency (30.1%), protein-rich food deficit (3.2% with 0–1 markers), insufficient fluid intake (13.5% < 3 cups), low self-perceived nutrition quality (2.6% «insufficient», 26.3% «do not know»), self-rated health «not good» (41.0%), and reduced mid-upper arm circumference (3.2%) and calf circumference (5.8%). Correlation analysis demonstrated a weak positive association between MNA scores and the Barthel Index (r s = 0.26) and SPPB (r s = 0.27), a weak-to-moderate negative association with GDS-15 (r s = –0.31), and weak negative associations with frailty screening (r s = –0.28) and pain (r s = –0.24). CONCLUSION . Malnutrition risk was identified in every fifth patient. Moderate appetite decline, weight loss, neuropsychological problems, polypharmacy and poor self-rated health were widespread among patients at risk of malnutrition. Insufficient protein and fluid intake was also statistically significant. Rank correlation analysis showed a strong relationship between poor nutritional status and depressive symptoms, while other statistically significant associations were less strong, emphasizing the multifactorial nature of nutritional status among older adults. This should be taken into account when diagnosing and treating malnutrition, especially focusing on depression, physical activity and pain. Dietary targets for correction are proposed based on the study's limitations, and the results may be useful for developing nutritional support protocols for geriatric care facilities in Russia.
- 6 September 2026
- Published by Autonomous non-profit organization-Society of Specialists in the Field Innovative Medical Technology in Russian Journal of Geriatric Medicine
- No. 3,p. 260-269
Open AccessAssessment of Nutritional Status in Older Adults Using the Mini Nutritional Assessment: Patterns of Impairments and Targets for Dietary Rehabilitation. Analysis of the Multicenter Prospective Study «POSTSCRIPTUM»
BACKGROUND . Frailty and related nutritional disorders are highly prevalent among older adults, especially in inpatient settings [1, 2]. The Mini Nutritional Assessment (MNA) is a validated tool that enables not only screening of nutritional status but also a more detailed evaluation of risk factors for developing malnutrition [3]. OBJECTIVE — to conduct a comprehensive evaluation of nutritional parameters in patients aged 60 years and older residing in care homes and geriatric centers in Moscow, to detail responses across MNA domains, to identify correlations with functional, psychoemotional and clinical parameters, and to propose targets for dietary interventions. MATERIALS AND METHODS. A multicenter prospective study (within the first phase of the «POSTSCRIPTUM» clinical trial) included 792 patients aged 60 years and older (mean age 76.8 ± 8.2 years, 68% women) with indications for geriatric rehabilitation. Nutritional assessment was performed using the full version of the MNA [3]. Based on the total score, patients were divided into two groups: «normal» (MNA ≥24, n = 636) and «at risk of malnutrition» (MNA < 24, n = 156). A comparative analysis of responses to each of the 18 MNA items was carried out, along with correlation analysis between the MNA score and age, body mass index (BMI), functional independence (Barthel Index, Lawton Index), physical performance (Short Physical Performance Battery, SPPB), muscle strength (handgrip dynamometry), cognitive status (Montreal Cognitive Assessment (MoCA), depression (15-item Geriatric Depression Scale, GDS-15), pain (Visual Analogue Scale, VAS score), insomnia (Insomnia Severity Index, ISI), polypharmacy, and frailty screening (score on the «Age Is Not a Hindrance» scale). RESULTS . The proportion of patients at risk of malnutrition was 19.7%. Statistically significant differences between groups were found across most MNA domains (p < 0.001). The following factors were significantly more frequent in the malnutrition-risk group: appetite decline (46.8% moderate and 1.3% severe), weight loss over the preceding 3 months (43.6%), mobility limitations (5.8%), acute stress/disease (69.2%), neuropsychological problems (overt dementia or depression —15.4%), polypharmacy (80.8%), pressure ulcers (2.6%), inadequate meal frequency (30.1%), protein-rich food deficit (3.2% with 0–1 markers), insufficient fluid intake (13.5% < 3 cups), low self-perceived nutrition quality (2.6% «insufficient», 26.3% «do not know»), self-rated health «not good» (41.0%), and reduced mid-upper arm circumference (3.2%) and calf circumference (5.8%). Correlation analysis demonstrated a weak positive association between MNA scores and the Barthel Index (r s = 0.26) and SPPB (r s = 0.27), a weak-to-moderate negative association with GDS-15 (r s = –0.31), and weak negative associations with frailty screening (r s = –0.28) and pain (r s = –0.24). CONCLUSION . Malnutrition risk was identified in every fifth patient. Moderate appetite decline, weight loss, neuropsychological problems, polypharmacy and poor self-rated health were widespread among patients at risk of malnutrition. Insufficient protein and fluid intake was also statistically significant. Rank correlation analysis showed a strong relationship between poor nutritional status and depressive symptoms, while other statistically significant associations were less strong, emphasizing the multifactorial nature of nutritional status among older adults. This should be taken into account when diagnosing and treating malnutrition, especially focusing on depression, physical activity and pain. Dietary targets for correction are proposed based on the study's limitations, and the results may be useful for developing nutritional support protocols for geriatric care facilities in Russia.
- Open Access
- 6 September 2026
- Published by Autonomous non-profit organization-Society of Specialists in the Field Innovative Medical Technology in Russian Journal of Geriatric Medicine
- No. 3,p. 238-248
FRAX® Offline: How Reliable is the Paper-Based Fracture Risk Calculation? A Review of Methods and Analysis of Therapeutic Intervention Thresholds
BACKGROUND . FRAX® is a key tool for fracture risk stratification in osteoporosis. In Russia, both online calculators and paper charts are available, but their comparability has not been studied. Offline settings, remote areas, and high patient flow make paper charts a practical alternative, yet their reliability is uncertain. OBJECTIVE . To assess the concordance between 10-year fracture probabilities calculated using the online FRAX® calculator and paper-based FRAX® charts developed for the Russian population. MATERIALS AND METHODS . This cross-sectional study included 161 patients (65.2% women) aged ≥50 years who were referred for DXA. Ten-year probabilities of major osteoporotic fractures (MOF) and hip fractures were calculated using two methods (online and paper charts), based on bone mineral density or body mass index (BMI). Correlation, regression, Bland–Altman analysis, and agreement on intervention thresholds were performed. RESULTS . No statistically significant differences were found (p > 0.05). The correlation ranged from ρ = 0.927 to 0.957 (p < 0.001) with R ² = 84–90%. The highest Cohen's kappa value was observed for the MOF risk using BMI (k = 0,749). The false-positive intervention threshold rate was 4.9–5.3%. CONCLUSION . Paper-based FRAX® charts show high concordance with the online calculator and can serve as a reliable alternative when internet access is limited or for large-scale screening.
- 6 September 2026
- Published by Autonomous non-profit organization-Society of Specialists in the Field Innovative Medical Technology in Russian Journal of Geriatric Medicine
- No. 3,p. 238-248
Open AccessFRAX® Offline: How Reliable is the Paper-Based Fracture Risk Calculation? A Review of Methods and Analysis of Therapeutic Intervention Thresholds
BACKGROUND . FRAX® is a key tool for fracture risk stratification in osteoporosis. In Russia, both online calculators and paper charts are available, but their comparability has not been studied. Offline settings, remote areas, and high patient flow make paper charts a practical alternative, yet their reliability is uncertain. OBJECTIVE . To assess the concordance between 10-year fracture probabilities calculated using the online FRAX® calculator and paper-based FRAX® charts developed for the Russian population. MATERIALS AND METHODS . This cross-sectional study included 161 patients (65.2% women) aged ≥50 years who were referred for DXA. Ten-year probabilities of major osteoporotic fractures (MOF) and hip fractures were calculated using two methods (online and paper charts), based on bone mineral density or body mass index (BMI). Correlation, regression, Bland–Altman analysis, and agreement on intervention thresholds were performed. RESULTS . No statistically significant differences were found (p > 0.05). The correlation ranged from ρ = 0.927 to 0.957 (p < 0.001) with R ² = 84–90%. The highest Cohen's kappa value was observed for the MOF risk using BMI (k = 0,749). The false-positive intervention threshold rate was 4.9–5.3%. CONCLUSION . Paper-based FRAX® charts show high concordance with the online calculator and can serve as a reliable alternative when internet access is limited or for large-scale screening.
- Open Access
- 6 September 2026
- Published by Autonomous non-profit organization-Society of Specialists in the Field Innovative Medical Technology in Russian Journal of Geriatric Medicine
- No. 3,p. 234-237
Review of Clinical Guidelines «Sarcopenia in Elderly Patients»
This review outlines the key points from the clinical guidelines «Sarcopenia in Elderly Patients», covering definition, epidemiology, clinical features, diagnostic approaches, and treatment strategies. The information is intended to help individuals manage patients aged 60 years or older with a focus on muscle health.
- 6 September 2026
- Published by Autonomous non-profit organization-Society of Specialists in the Field Innovative Medical Technology in Russian Journal of Geriatric Medicine
- No. 3,p. 234-237
Open AccessReview of Clinical Guidelines «Sarcopenia in Elderly Patients»
This review outlines the key points from the clinical guidelines «Sarcopenia in Elderly Patients», covering definition, epidemiology, clinical features, diagnostic approaches, and treatment strategies. The information is intended to help individuals manage patients aged 60 years or older with a focus on muscle health.
- 29 June 2026
- Published by Russian Dialysis Society in Nephrology and Dialysis
- Vol. 28 (2)
Common pathogenetic pathways in the development of sarcopenia in patients with chronic kidney disease and metabolic disorders
Sarcopenia is a syndrome characterized by the progressive and generalized loss of skeletal muscle mass, strength, and physical performance, leading to an increased risk of adverse outcomes, particularly in elderly individuals, including impaired quality of life, disability, and mortality. Chronic kidney disease (CKD) is a condition associated with accelerated aging that contributes to disturbances in nutritional and functional status, thereby predisposing patients, especially whose with end-stage kidney disease, to an increased risk of sarcopenia. Sarcopenia is considered one of the major geriatric syndromes, while CKD is recognized as an important risk factor for the development of metabolic disturbances and chronic systemic inflammation. The main pathogenetic mechanisms of sarcopenia include mitochondrial dysfunction, age-related degeneration of motor neuron end plates, excessive apoptosis, decreased nitric oxide production, androgen deficiency, reduced activity of satellite and stem cells, systemic inflammation, and glucocorticoid exposure. CKD is accompanied by multiple metabolic and hormonal abnormalities, including metabolic acidosis, uremia, hyperparathyroidism, and disturbances in increased insulin-like growth factor (IGF) signaling, all of which negatively affect muscle metabolism and increase the risk of sarcopenia. Intestinal dysbiosis is also considered as a potential mechanism contributing to CKD progression, and may indirectly influence muscle. Several studies have demonstrated an association between loss of muscle mass and deterioration of kidney function, including in patients with sarcopenic obesity. Muscle mass is an important determinant of longevity in the older adults, whereas sarcopenic obesity represent a significant risk factor for adverse health outcomes. However, the prevalence and clinical significance of sarcopenic obesity in patients with CKD remains insufficiently investigated. Systematic reviews have shown that sarcopenia in CKD patients is associated with multiple adverse clinical outcomes, including falls, fractures, and cardiovascular events. Despite the large number of studies examining these processes, the precise molecular pathways and interactions leading to muscular atrophy remain incompletely understood. Moreover, relatively few systematic reviews and meta-analyses have summarized the prevalence of sarcopenia in CKD, and most available data are limited to dialysis patients and kidney transplant recipients.
- 29 June 2026
- Published by Russian Dialysis Society in Nephrology and Dialysis
- Vol. 28 (2)
Common pathogenetic pathways in the development of sarcopenia in patients with chronic kidney disease and metabolic disorders
Sarcopenia is a syndrome characterized by the progressive and generalized loss of skeletal muscle mass, strength, and physical performance, leading to an increased risk of adverse outcomes, particularly in elderly individuals, including impaired quality of life, disability, and mortality. Chronic kidney disease (CKD) is a condition associated with accelerated aging that contributes to disturbances in nutritional and functional status, thereby predisposing patients, especially whose with end-stage kidney disease, to an increased risk of sarcopenia. Sarcopenia is considered one of the major geriatric syndromes, while CKD is recognized as an important risk factor for the development of metabolic disturbances and chronic systemic inflammation. The main pathogenetic mechanisms of sarcopenia include mitochondrial dysfunction, age-related degeneration of motor neuron end plates, excessive apoptosis, decreased nitric oxide production, androgen deficiency, reduced activity of satellite and stem cells, systemic inflammation, and glucocorticoid exposure. CKD is accompanied by multiple metabolic and hormonal abnormalities, including metabolic acidosis, uremia, hyperparathyroidism, and disturbances in increased insulin-like growth factor (IGF) signaling, all of which negatively affect muscle metabolism and increase the risk of sarcopenia. Intestinal dysbiosis is also considered as a potential mechanism contributing to CKD progression, and may indirectly influence muscle. Several studies have demonstrated an association between loss of muscle mass and deterioration of kidney function, including in patients with sarcopenic obesity. Muscle mass is an important determinant of longevity in the older adults, whereas sarcopenic obesity represent a significant risk factor for adverse health outcomes. However, the prevalence and clinical significance of sarcopenic obesity in patients with CKD remains insufficiently investigated. Systematic reviews have shown that sarcopenia in CKD patients is associated with multiple adverse clinical outcomes, including falls, fractures, and cardiovascular events. Despite the large number of studies examining these processes, the precise molecular pathways and interactions leading to muscular atrophy remain incompletely understood. Moreover, relatively few systematic reviews and meta-analyses have summarized the prevalence of sarcopenia in CKD, and most available data are limited to dialysis patients and kidney transplant recipients.
- Open Access
- 26 April 2026
- Published by Endocrinology Research Centre in Bulletin of Reproductive Health
- No. 1,p. 40-69
Russian eligibility criteria for prescription of menopausal hormone therapy to patients with cardiovascular and metabolic diseases. Agreement document of RKO, ROAG, RAE, EAT, AFR, RNMOT, RAGG
Menopausal symptoms can disrupt the lives of women at the peak of their careers and family life. Currently, the most effective treatment for these symptoms is menopausal hormone therapy (MHT). The presence of cardiovascular and metabolic diseases does not preclude the use of MHT to relieve menopausal symptoms and improve quality of life. However, physicians’ concerns about causing more harm than good often hinder the use of this type of hormone therapy. Caution is especially important when it comes to women with comorbidities. Moreover, it should be acknowledged that high-quality studies on the safety of MHT for major chronic noncommunicable diseases and common comorbid conditions are insufficient. This consensus document analyzes all currently available data from clinical trials of various designs and develops a set of eligibility criteria for prescribing MHT to women with comorbid cardiovascular and metabolic diseases. Based on this document, physicians of various specialties who consult with women in menopause will receive an accessible algorithm that will allow them to avoid potentially dangerous situations and appropriately prescribe HRT in clinical practice
- 26 April 2026
- Published by Endocrinology Research Centre in Bulletin of Reproductive Health
- No. 1,p. 40-69
Open AccessRussian eligibility criteria for prescription of menopausal hormone therapy to patients with cardiovascular and metabolic diseases. Agreement document of RKO, ROAG, RAE, EAT, AFR, RNMOT, RAGG
Menopausal symptoms can disrupt the lives of women at the peak of their careers and family life. Currently, the most effective treatment for these symptoms is menopausal hormone therapy (MHT). The presence of cardiovascular and metabolic diseases does not preclude the use of MHT to relieve menopausal symptoms and improve quality of life. However, physicians’ concerns about causing more harm than good often hinder the use of this type of hormone therapy. Caution is especially important when it comes to women with comorbidities. Moreover, it should be acknowledged that high-quality studies on the safety of MHT for major chronic noncommunicable diseases and common comorbid conditions are insufficient. This consensus document analyzes all currently available data from clinical trials of various designs and develops a set of eligibility criteria for prescribing MHT to women with comorbid cardiovascular and metabolic diseases. Based on this document, physicians of various specialties who consult with women in menopause will receive an accessible algorithm that will allow them to avoid potentially dangerous situations and appropriately prescribe HRT in clinical practice
- Open Access
- 25 April 2026
- Published by Autonomous non-profit organization-Society of Specialists in the Field Innovative Medical Technology in Russian Journal of Geriatric Medicine
- No. 2,p. 185-195
Osteoporosis in the long-lived: focus on safety and quality of life
Osteoporosis in the elderly (≥90 years) is a key factor in disability and mortality due to the high risk of fractures, particularly at the hip. The leading role in the pathogenesis is played not so much by decreased bone mineral density but by deterioration of bone microarchitecture, sarcopenia, chronic inflammation, and a high rate of falls. Diagnosis with standard methods is often difficult, and treatment requires a comprehensive geriatric approach. Modern medications (bisphosphonates, denosumab, and teriparatide) are effective; however, their use requires strict individualization, taking into account comorbidities, renal function, and life expectancy. Oral bisphosphonates, particularly ibandronic acid, with once-monthly dosing, demonstrate a favorable safety and efficacy profile even in the very elderly. Fall prevention and nutritional management are key.
- 25 April 2026
- Published by Autonomous non-profit organization-Society of Specialists in the Field Innovative Medical Technology in Russian Journal of Geriatric Medicine
- No. 2,p. 185-195
Open AccessOsteoporosis in the long-lived: focus on safety and quality of life
Osteoporosis in the elderly (≥90 years) is a key factor in disability and mortality due to the high risk of fractures, particularly at the hip. The leading role in the pathogenesis is played not so much by decreased bone mineral density but by deterioration of bone microarchitecture, sarcopenia, chronic inflammation, and a high rate of falls. Diagnosis with standard methods is often difficult, and treatment requires a comprehensive geriatric approach. Modern medications (bisphosphonates, denosumab, and teriparatide) are effective; however, their use requires strict individualization, taking into account comorbidities, renal function, and life expectancy. Oral bisphosphonates, particularly ibandronic acid, with once-monthly dosing, demonstrate a favorable safety and efficacy profile even in the very elderly. Fall prevention and nutritional management are key.